Viewing data from:

DAPTOMYCIN

ANDA

DAPTOMYCIN | A213966 | MYLAN PHARMACEUTICALS INC A VIATRIS CO

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: DAPTOMYCIN(TE code: AP)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Cubist Pharmaceuticals LLC v. Mylan Pharmaceuticals Inc. et al 1:2020cv00052 2 patentsANDA 213966	N.D. W. Va.	2020-03-24	Terminated 2021-11-05	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$21.85

per ea

Lowest NADAC/Unit

$21.85

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
67457094115DAPTOMYCIN 500 MG VIAL	$21.85	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain13 active DMFs2 inactive

9 active API suppliers hold Drug Master Files for this ingredient.

OLON SPADAPTOMYCIN

DMF 229232009

XELLIA PHARMACEUTICALS APSDAPTOMYCIN

DMF 266042012

ZHEJIANG MEDICINE CO LTDDAPTOMYCIN

DMF 267782013

XELLIA PHARMACEUTICALS APSDAPTOMYCIN NON-STERILE

DMF 271792013

CHONGQING DAXIN PHARMACEUTICAL CO LTDDAPTOMYCIN, NON-STERILE, BULK DRUG

DMF 297602015

LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDDAPTOMYCIN

DMF 298592015

CHENGDU YACHT BIOTECHNOLOGY CO LTDDAPTOMYCIN

DMF 305922016

CHENGDU YACHT BIOTECHNOLOGY CO LTDDAPTOMYCIN

DMF 330042018

HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTDDAPTOMYCIN

DMF 336712019

LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDDAPTOMYCIN (PROCESS II)

DMF 347212020

CKD BIO CORPDAPTOMYCIN

DMF 347572020

CHONGQING DAXIN PHARMACEUTICAL CO LTDDAPTOMYCIN

DMF 352412020

FUJIAN COMHONY BIOTECHNOLOGY CO LTDDAPTOMYCIN

DMF 429892025

ZHEJIANG HISUN PHARMACEUTICAL CO LTDInactiveDAPTOMYCIN

DMF 247232011

LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDInactiveDAPTOMYCIN

DMF 291372015

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 500MG/VIAL

0 patents0 exclusivities▴

POWDER;INTRAVENOUS | Approved: Aug 7, 2023

No patent or exclusivity listings for this strength.